Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 9,580,504

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,580,504
Title:Pidilizumab monoclonal antibody therapy following stem cell transplantation
Abstract: Methods for treating specific populations of cancer patients, specifically patients suffering from cancer who undergo stem cell transplantation and were classified as positive by a pre-transplant metabolic imaging, by administering to the subject a therapeutically effective amount of a pidilizumab monoclonal antibody.
Inventor(s): Rotem-Yehudar; Rinat (Tel Aviv, IL), Schickler; Michael (Mazkeret Batya, IL)
Assignee: CureTech Ltd. (Yavne, IL)
Application Number:14/536,343
Patent Claims:see list of patent claims

Details for Patent 9,580,504

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Try it Free 2033-11-07
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 2002-02-19 ⤷  Try it Free 2033-11-07
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 2017-06-22 ⤷  Try it Free 2033-11-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.